Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Chrna7 deficient mice manifest no consistent neuropsychiatric and behavioral phenotypes.

Yin J, Chen W, Yang H, Xue M, Schaaf CP.

Sci Rep. 2017 Jan 3;7:39941. doi: 10.1038/srep39941.

2.

The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.

Haig G, Wang D, Othman AA, Zhao J.

Neuropsychopharmacology. 2016 Nov;41(12):2893-2902. doi: 10.1038/npp.2016.101.

PMID:
27319970
3.

Brain-specific Crmp2 deletion leads to neuronal development deficits and behavioural impairments in mice.

Zhang H, Kang E, Wang Y, Yang C, Yu H, Wang Q, Chen Z, Zhang C, Christian KM, Song H, Ming GL, Xu Z.

Nat Commun. 2016 Jun 1;7. doi: 10.1038/ncomms11773.

4.
5.

Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders.

Kalkman HO, Feuerbach D.

Cell Mol Life Sci. 2016 Jul;73(13):2511-30. doi: 10.1007/s00018-016-2175-4. Review.

6.

nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

Parikh V, Kutlu MG, Gould TJ.

Schizophr Res. 2016 Mar;171(1-3):1-15. doi: 10.1016/j.schres.2016.01.020. Review.

PMID:
26803692
7.

Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial.

Smith RC, Amiaz R, Si TM, Maayan L, Jin H, Boules S, Sershen H, Li C, Ren J, Liu Y, Youseff M, Lajtha A, Guidotti A, Weiser M, Davis JM.

PLoS One. 2016 Jan 5;11(1):e0143490. doi: 10.1371/journal.pone.0143490.

8.

Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis.

Roberts E, Eden Evins A, McNeill A, Robson D.

Addiction. 2016 Apr;111(4):599-612. doi: 10.1111/add.13236. Review.

PMID:
26594837
9.

Neuronal effects of nicotine during auditory selective attention in schizophrenia.

Smucny J, Olincy A, Rojas DC, Tregellas JR.

Hum Brain Mapp. 2016 Jan;37(1):410-21. doi: 10.1002/hbm.23040. Erratum in: Hum Brain Mapp. 2016 Jul;37(7):2710.

10.

Role of presynaptic phosphoprotein synapsin II in schizophrenia.

Molinaro L, Hui P, Tan M, Mishra RK.

World J Psychiatry. 2015 Sep 22;5(3):260-72. doi: 10.5498/wjp.v5.i3.260.

11.

Molecular substrates of schizophrenia: homeostatic signaling to connectivity.

Landek-Salgado MA, Faust TE, Sawa A.

Mol Psychiatry. 2016 Jan;21(1):10-28. doi: 10.1038/mp.2015.141. Review.

12.

Nicotinic receptor contributions to smoking: insights from human studies and animal models.

Brunzell DH, Stafford AM, Dixon CI.

Curr Addict Rep. 2015 Mar;2(1):33-46.

13.

Development of [(18)F]ASEM, a specific radiotracer for quantification of the α7-nAChR with positron-emission tomography.

Horti AG.

Biochem Pharmacol. 2015 Oct 15;97(4):566-75. doi: 10.1016/j.bcp.2015.07.030. Review.

14.

Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders.

Terry AV Jr, Callahan PM, Hernandez CM.

Biochem Pharmacol. 2015 Oct 15;97(4):388-98. doi: 10.1016/j.bcp.2015.07.027. Review.

15.

Long-lasting changes in neural networks to compensate for altered nicotinic input.

John D, Berg DK.

Biochem Pharmacol. 2015 Oct 15;97(4):418-24. doi: 10.1016/j.bcp.2015.07.020. Review.

16.

Prenatal choline and the development of schizophrenia.

Freedman R, Ross RG.

Shanghai Arch Psychiatry. 2015 Apr 25;27(2):90-102. doi: 10.11919/j.issn.1002-0829.215006. Review.

17.

Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.

Smucny J, Stevens KE, Olincy A, Tregellas JR.

Transl Psychiatry. 2015 Jun 23;5:e587. doi: 10.1038/tp.2015.77. Review.

18.

Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.

Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC.

Schizophr Bull. 2016 Mar;42(2):335-43. doi: 10.1093/schbul/sbv072.

PMID:
26071208
20.

cAMP-dependent protein kinase inhibits α7 nicotinic receptor activity in layer 1 cortical interneurons through activation of D1/D5 dopamine receptors.

Komal P, Estakhr J, Kamran M, Renda A, Nashmi R.

J Physiol. 2015 Aug 15;593(16):3513-32. doi: 10.1113/JP270469.

Items per page

Supplemental Content

Support Center